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Abstract
IMPORTANCE Although the heart team approach is recommended in revascularization guidelines,
the frequency with which heart team decisions differ from those of the original treating
interventional cardiologist is unknown.
OBJECTIVE To examine the difference in decisions between the heart team and the original treating
interventional cardiologist for the treatment of patients with multivessel coronary artery disease.
DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, 245 consecutive patients with
multivessel coronary artery disease were recruited from 1 high-volume tertiary care referral center
(185 patients were enrolled through a screening process, and 60 patients were retrospectively
enrolled from the center’s database). A total of 237 patients were included in the final virtual heart
team analysis. Treatment decisions (which comprised coronary artery bypass grafting, percutaneous
coronary intervention, and medication therapy) were made by the original treating interventional
cardiologists between March 15, 2012, and October 20, 2014. These decisions were then compared
with pooled-majority treatment decisions made by 8 blinded heart teams using structured online
case presentations between October 1, 2017, and October 15, 2018. The randomized members of the
heart teams comprised experts from 3 domains, with each team containing 1 noninvasive
cardiologist, 1 interventional cardiologist, and 1 cardiovascular surgeon. Cases in which all 3 of the
heart team members disagreed and cases in which procedural discordance occurred (eg, 2 members
chose coronary artery bypass grafting and 1 member chose percutaneous coronary intervention)
were discussed in a face-to-face heart team review in October 2018 to obtain pooled-majority
decisions. Data were analyzed from May 6, 2019, to April 22, 2020.
MAIN OUTCOMES AND MEASURES The Cohen κ coefficient between the treatment
recommendation from the heart team and the treatment recommendation from the original treating
interventional cardiologist.
RESULTS Among 234 of 237 patients (98.7%) in the analysis for whom complete data were
available, the mean (SD) age was 67.8 (10.9) years; 176 patients (75.2%) were male, and 191 patients
(81.4%) had stenosis in 3 epicardial coronary vessels. A total of 71 differences (30.3%; 95% CI,
24.5%-36.7%) in treatment decisions between the heart team and the original treating
interventional cardiologist occurred, with a Cohen κ of 0.478 (95% CI, 0.336-0.540; P = .006). The
heart team decision was more frequently unanimous when it was concordant with the decision of the
original treating interventional cardiologist (109 of 163 cases [66.9%]) compared with when it was




recommended by a heart team differ
from those recommended by an original
treating interventional cardiologist for
patients with multivessel coronary
artery disease?
Findings In this cross-sectional study of
245 patients with multivessel coronary
artery disease, heart team treatment
recommendations indicated moderate
agreement (with discordance in 30% of
cases) with the original treating
interventional cardiologist. Unanimous
decisions within the heart team and
agreement between the heart team
interventional cardiologist and the
original treating interventional
cardiologist were less frequent in this
subset of cases, while interventional
cardiologist recommendations for
angioplasty and medication therapy
were more frequent.
Meaning The study’s findings indicated
that heart team recommendations
differed from those of the original
treating interventional cardiologist in
approximately one-third of cases; this
subset of cases was associated with a
greater number of divergent opinions
between interventional cardiologists
and within the heart team.
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Abstract (continued)
treatment decision, there was more agreement between the heart team interventional cardiologist
and the original treating interventional cardiologist (138 of 163 cases [84.7%]) compared with when
the heart team disagreed with the original treatment decision (14 of 71 cases [19.7%]); P < .001).
Those with an original treatment of coronary artery bypass grafting, percutaneous coronary
intervention, and medication therapy, 32 of 148 patients [22.3%], 32 of 71 patients [45.1%], and 6 of
15 patients [40.0%], respectively, received a different treatment recommendation from the heart
team than the original treating interventional cardiologist; the difference across the 3 groups was
statistically significant (P = .002).
CONCLUSIONS AND RELEVANCE The heart team’s recommended treatment for patients with
multivessel coronary artery disease differed from that of the original treating interventional
cardiologist in up to 30% of cases. This subset of cases was associated with a lower frequency of
unanimous decisions within the heart team and less concordance between the interventional
cardiologists; discordance was more frequent when percutaneous coronary intervention or
medication therapy were considered. Further research is needed to evaluate whether heart team
decisions are associated with improvements in outcomes and, if so, how to identify patients for
whom the heart team approach would be beneficial.
JAMA Network Open. 2020;3(8):e2012749. doi:10.1001/jamanetworkopen.2020.12749
Introduction
In guidelines for revascularization, the heart team model has been given the highest level of
recommendation (class 1 in the American College of Cardiology/American Heart Association
guidelines) for treatment decision-making in patients with complex multivessel coronary artery
disease (CAD); however, this recommendation was primarily based on consensus opinion
(considered level C evidence in the American College of Cardiology/American Heart Association
guidelines).1-3 The goal of a heart team is to use multidisciplinary expertise in decision-making for the
treatment of patients with complex conditions. Although the membership of a heart team can vary,
it generally includes an interventional cardiologist, a cardiovascular surgeon, and a noninvasive
cardiologist. Although, to our knowledge, no randomized clinical trials have been conducted to
evaluate the benefits of the heart team approach with regard to decision-making or outcomes,
observational data suggest that heart team–derived management decisions are safe, and the
implementation of heart team decision-making is associated with improvements in patient
outcomes.4-6 Furthermore, the use of group decision-making, commonly referred to as collective
intelligence, has been associated with improvements in decision-making in multiple settings.7-11
Heart team decisions for patients with multivessel CAD also have face validity. Decisions by
heart teams have been reported to be feasible, reproducible, and reasonably concordant with the
Appropriate Use Criteria for Coronary Revascularization.4,12-14 Multivessel CAD is a complex condition
with multiple layers of interacting variables, including objective anatomical data from angiography,
functional data, clinical data (symptoms and comorbidities), sociodemographic variables, and patient
values and goals. Often, variables within the same patient may indicate competing treatment
strategies. The expertise of individual physicians or surgeons is specific to their professional training
and experience.15 Hence, the use of multiple perspectives may balance competing variables and
reduce potential specialty-associated biases.16
However, implementation of the heart team approach is resource intensive.14 It requires
coordination of multiple schedules, administrative infrastructure to collate and organize data,
determination of standardized risk scores (SYNTAX score [developed in the Synergy Between PCI
(percutaneous coronary intervention) With Taxus and Cardiac Surgery, or SYNTAX, clinical trial],
European System for Cardiac Operative Risk Evaluation [EuroSCORE] score, and Society of Thoracic
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Surgeons [STS] score), coordination of case information by central triage, and communication of
consensus decisions to referring physicians.17 As such, it can be challenging to integrate a heart team
into the workflow of high-volume medical centers.17 Furthermore, time-sensitive decisions for acute
presentations may be challenging to coordinate. Hence, it is important to assess whether heart team
decision-making would be any different than existing decision-making structures. The extent of
difference between the decision-making of the individual physician and the heart team is
currently unknown.
Previous studies have indicated that, in patients with multivessel CAD, the treatment decision
recommended by the original treating interventional cardiologist is the best indicator of the final
treatment received.18 We sought to examine the agreement between the original treating
interventional cardiologist and the heart team regarding treatment decisions for patients with
multivessel CAD.
Methods
This study was approved by the Hamilton Integrated Research Ethics Board with a waiver of informed
consent for patients because the study presented a low risk to them. All physicians and surgeons
involved in the study provided written consent. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline was used for this study.
Patient Population and Recruitment
Multivessel CAD was defined as (1) stenosis of 70% or more in 3 epicardial coronary vessels or
stenosis of at least 1.5 mm in their branches or (2) stenosis in 2 epicardial coronary vessels with
involvement of the proximal left anterior descending artery.19,20 Patients with stable CAD and
patients with presentations of unstable angina or non–ST-segment elevation myocardial infarction
were included. Patients who had acute ST-segment elevation myocardial infarction, who were
hemodynamically unstable, or who had a clear independent indication for cardiac surgery (eg, severe
aortic stenosis or left main stenosis of 50%) were excluded.
A total of 771 patients who had multivessel CAD between July 17, 2012, and October 20, 2014
were screened at 1 high-volume tertiary care referral center (Figure 1A). Of those, 310 patients were
eligible for participation; 125 of those patients were excluded because the original treating
interventional cardiologist was unable to complete the interview owing to time constraints. For the
remaining 185 patients, the actual treatments received and the most important factors underlying
the original treatment decisions were documented at the time of the angiogram through a
questionnaire administered by our research assistants. An additional 60 patients with approximately
the same distribution of original treatment recommendations (CABG [coronary artery bypass
grafting], PCI, or medication therapy) from March 15 to August 3, 2012, were consecutively retrieved
from our center’s database (using multivessel coronary artery disease as the search term) to reach
our final sample of 245 patients. Because there was no formal heart team at our center at the time of
this study, all treatment decisions (even those for cases that were retrospectively recruited) were
those of the individual interventional cardiologist at the time of the angiogram. Five additional
patients were excluded after the core laboratory review, and 3 patients were excluded based on
clinical criteria during preparation for the final case presentation via the virtual heart team interface,
resulting in 237 patients included in the virtual heart team analysis. The flowchart for case inclusion
in the final heart team analysis is detailed in Figure 1B.
Interventional Cardiologists and Heart Team
Almost all of the original treating interventional cardiologists had more than 10 years of experience,
with 1 cardiologist having between 5 and 10 years of experience. Each interventional cardiologist
performed 750 diagnostic angiograms, 250 to 300 diagnostic PCIs, and 90 to 100 primary PCIs
annually.
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Clinical summaries, diagnostic angiogram (dynamic cine) images, SYNTAX scores (which
calculate CAD complexity, with higher scores indicating greater complexity),21 STS scores (which
estimate the risk of morbidity and mortality after surgery, with higher scores indicating higher
risk),22-24 and EuroSCOREs (which calculate the risk of mortality after cardiac surgery, with higher
scores indicating higher risk)22,23,25 were collated by 2 senior cardiology trainees (S.G. and N.G.) and
presented via a virtual heart team interface. Clinical summaries included all medical histories,
medications, physical examination results (including body mass index [calculated as weight in
kilograms divided by height in meters squared]), and social histories (including occupation, living
situation, social support, level of independence with activities of daily living, and mobility),
laboratory findings, 12-lead electrocardiogram results, noninvasive stress testing results, and
echocardiogram results. These summaries were obtained through a medical record review by the
cardiology trainees and presented using a structured template (eMethods in the Supplement). All
Figure 1. Patient Selection and Heart Team Decision Flowcharts
310 Met inclusion criteria
237 Included in virtual heart team analysis
245 Selected
185 From screened population
60 From retrospective data
461 Excluded
238 Did not meet angiographic criteria
118 Had previous bypass surgery
43 Were outside screening window
30 Physicians declined participation
14 Had ST segment elevation MI
11 Received treatment from noninterventional physicians
6 Had another indication for cardiac surgery
1 Was hemodynamically unstable
5 Excluded after core laboratory evaluation
3 Did not meet angiographic criteria
2 Were repeat cases
3 Excluded during case presentation preparation
2 Had insufficient clinical data
1 Had moderate aortic stenosis
125 Excluded (physicians unable to complete point-of-care
interviews owing to workflow conflicts)
771 Patients screened
Patient selection processA
8 Heart teams (3 members per team) exposed] to peer treatment decisions and rationales
234 of 237 Asynchronous independent case reviews completed by heart team
118 Unanimous decisions 85 Majority decisions 23 Procedural disagreements 8 Complete disagreements
31 Face-to-face heart team
(7 members per team) reviews
31 Final heart team treatment decisions203 Final heart team treatment decisions
Heart team decision processB
MI indicates myocardial infarction. A, Patient selection
process. B, Heart team decision process. Unanimous
decisions were those in which all 3 of the team
members arrived at the same decision. Majority
decisions were those in which 2 of 3 team members
made the same decision. Procedural disagreements
were those in which 2 team members chose a
procedural treatment and 1 member disagreed with
that treatment. Complete disagreements were those
in which all 3 of the team members arrived at different
treatment decisions. Face-to-face heart team reviews
were held only when procedural disagreements or
complete disagreements with the heart team
occurred.
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SYNTAX scores were calculated by 2 interventional cardiologists (M.B.T. and M.G.S.) using core
laboratory software (QAngio XA; Medis); the 2 cardiologists were blinded to the original treatment
assignments.
Eight 3-member heart teams with randomized membership (each containing 1 interventional
cardiologist, 1 cardiovascular surgeon, and 1 noninvasive cardiologist) independently evaluated 237
cases through the virtual heart team interface using structured online case presentations and cine
angiogram images of patients with multivessel CAD. Cases were randomized into 6 sets of 5 cases
each (approximately 30 cases per heart team) using a stratified randomization procedure to ensure
relatively equal heart team exposure to case complexity and a similar ratio of original treatment
strategies (CABG, PCI, and medication therapy).
Each heart team member’s decision was initially made asynchronously and independently, with
the member blinded to other team members, the decisions of other team members, and the decision
of the original treating interventional cardiologist. The decisions of individual heart team members
and the 3 primary reasons for each of their decisions were acquired between October 1, 2017, and
October 30, 2018. The heart team members had access to the responses of the other heart team
members only after all members had submitted their independent decisions; a change in decision
was then allowed.
Comparison and Main Outcomes
Interrater reliability between the heart team and the original treating interventional cardiologist was
measured by the Cohen κ coefficient and the frequency of agreement and disagreement. In all cases,
the pooled-majority decision from the heart team was compared with the treatment decision of the
original treating interventional cardiologist.
For the initial 3-member heart team online review, either the unanimous decision (all 3 of the
heart team members chose the same treatment) or the majority decision (2 of the 3 heart team
members chose the same treatment) from the virtual heart team interface was considered the final
heart team management decision (Figure 1B). Cases in which all 3 of the heart team members
disagreed or in which procedural discordance occurred (eg, 2 members chose CABG, but the surgeon
chose medication therapy) were reconciled on a face-to-face basis by a 7-member heart team (3
interventional cardiologists, 2 general cardiologists, and 2 cardiovascular surgeons), which
comprised a subset of the entire heart team cohort who volunteered to participate in the process
(Figure 1B). After face-to-face discussions, heart team members submitted their decisions
independently, using an electronic interface to arrive at a majority decision. The heart team
evaluation process for included cases is detailed in Figure 1B.
For the post hoc subgroup analyses, we first stratified the agreement and disagreement by (1)
unanimous vs majority decision within the heart team, (2) original treatment recommendation
received by the patient, and (3) agreement or disagreement between the heart team interventional
cardiologist vs the original treating interventional cardiologist. Second, we assessed the frequency of
treatment strategies between the heart team vs the original treating interventional cardiologist and
performed the same comparison between the different members of the heart team (noninvasive
cardiologist, cardiovascular surgeon, and interventional cardiologist). Third, we performed pairwise
comparisons of treatments between experts from different domains (eg, heart team interventional
cardiologist vs original treating interventional cardiologist, heart team interventional cardiologist vs
heart team cardiovascular surgeon, or heart team interventional cardiologist vs heart team
noninvasive cardiologist) to evaluate the extent of agreement. Fourth, we evaluated the number of
cases in which patient preference was an important factor in the treatment decision of the original
treating interventional cardiologist.
Sample Size
The goal of the study was to estimate the agreement, as measured by the Cohen κ statistic, between
the 2 methods of classifying cases (original treating interventional cardiologist vs heart team). To our
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knowledge, no estimates of the κ statistic comparing the 2 types of classification have been reported
in the literature. Only estimates of agreement between potential heart team members
(cardiovascular surgeons, interventional cardiologists, and noninvasive cardiologists) for a series of 6
cases have been reported (κ = 0.44).16 Hence, our sample size calculation was based on an
acceptable range of precision for the point estimate.
We assumed that for a sample size of 200, allowing for the true value of the interclass κ
coefficient to range from 0.286 to 0.792, a 2-sided 95% CI for the interclass κ statistic would extend
from the observed value of κ by 0.142 at the lower estimates and by 0.086 at the highest estimate.
That assumption was based on an approximate prevalence of CABG ranging from 60% to 70% of the
total sample at our center, as derived from our pilot data as well as data from the Variations in
Revascularization Practice in Ontario database for a low to medium PCI to CABG ratio, which is the
ratio represented by our center.18
Statistical Analysis
The Cohen κ statistic, calculated from the standard 2 by 2 table, was used to examine overall
agreement between the heart team and the individual cardiologist regarding the primary and
secondary outcomes. The generally accepted levels of agreement based on the κ statistic are as
follows: 0.01 to 0.20, indicating slight agreement; 0.21 to 0.40, indicating fair agreement; 0.41 to
0.60, indicating moderate agreement; 0.61 to 0.80, indicating substantial agreement; and 0.81 to
0.99, indicating almost perfect agreement. The strength of agreement, as described by the κ
statistic, has been previously defined.26 The 95% CI for the κ coefficient was also calculated. Baseline
comparisons across the original 3 treatment strategies were statistically compared using an χ2 test
for categorical variables and an analysis of variance for continuous variables. A 2-tailed P < .05 was
considered statistically significant. Statistical analyses were performed using SAS software, version
9.2 (SAS Institute Inc). Data were analyzed from May 6, 2019, to April 22, 2020.
Results
Of the 237 patients included in the heart team analysis, complete data were available for 234 patients
(98.7%). Among those, the mean (SD) age was 67.8 (10.9) years; 176 patients (75.2%) were male,
and 191 patients (81.4%) had stenosis in 3 epicardial coronary vessels. The baseline patient
characteristics are summarized in Table 1. Significant differences were found between patients based
on original treatment strategy, including differences in age, diabetes status, cognitive dysfunction,
angiogram characteristics, SYNTAX scores, EuroSCOREs, STS scores for mortality, and body mass
index (Table 1).
A paired analysis of the original treatment decisions vs the heart team treatment decisions
revealed a κ coefficient of 0.478 (95% CI, 0.336-0.540; P = .006), which was consistent with
moderate agreement (Table 2). This finding was based on 71 differences (30.3%; 95% CI,
24.5%-36.7%) between treatment recommendations made by the heart team and those made by
the original treating interventional cardiologist (Table 2). Of those with an original treatment
recommendation for CABG, PCI, and medication therapy, 32 of 148 patients (22.3%), 32 of 71 patients
(45.1%), and 6 of 15 patients (40.0%), respectively, received a different treatment recommendation
from the heart team review than from the original treating interventional cardiologist; this difference
across the 3 groups was statistically significant (P = .002) (Figure 2A). Of the 234 cases that received
a complete Heart Team review, 31 cases (13.2%) required face-to-face reviews owing to complete
disagreement between all members (8 of 31 cases) or procedural discordance (23 of 31 cases).
The heart team decision was more frequently unanimous when it was concordant with the
decision of the original treating interventional cardiologist (109 of 163 cases [66.9%]) compared with
when it was discordant (28 of 71 cases [39.4%]; P < .001) (Table 2). When the heart team agreed with
the original treatment decision, the decision of the heart team interventional cardiologist was more
frequently in agreement with that of the original treating interventional cardiologist (138 of 163 cases
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[84.7%]) compared with when the heart team disagreed with the original treatment decision (14 of
71 cases [19.7%]; P < .001) (Figure 2B).
The frequency with which the 3 treatment strategies were chosen by the heart team and the
original treating interventional cardiologist is represented in Figure 3A. The overall frequency of
treatment recommendations was not significantly different between the original treating
interventional cardiologist and the heart team for CABG (148 of 237 patients [62.4%] vs 140 of 234
patients [59.8%], respectively; P = .62) or PCI (74 of 237 patients [31.2%] vs 60 of 234 patients
[25.6%], respectively; P = .15) . However, medication therapy was less frequently recommended by
the original treating interventional cardiologist than by the heart team (15 of 237 patients [6.3%] vs
34 of 234 patients [14.5%], respectively; P = .004).
Table 1. Baseline Characteristics of Patients Included in Final Analysis Stratified
by Original Treatment Recommendation Received
Characteristic











Age, mean (SD), y 67.8 (10.9) 66.7 (9.7) 68.3
(12.7)
74.9 (10.5) .02
Male sex 176 (75.2) 116 (78.4) 51 (71.8) 9 (60.0) .21
Treatment indication




123 (52.6) 69 (46.6) 46 (64.8) 8 (53.3)
Reperfused STEMI 2 (0.9) 1 (0.7) 1 (1.4) 0
Ventricular arrhythmia 3 (1.3) 1 (0.7) 2 (2.8) 0
Cardiomyopathy or CHF 9 (3.8) 8 (5.4) 1 (1.4) 0
Comorbidities
Previous MI 38 (16.2) 21 (14.2) 12 (16.9) 5 (33.3) .16
Diabetes 99 (42.3) 72 (48.6) 21 (29.6) 6 (40) .03
Renal dysfunction 44 (18.8) 25 (16.9) 16 (22.5) 3 (20.0) .62
Dialysis 9 (3.8) 8 (5.4) 1 (1.4) 0 .26
COPD 18 (7.7) 9 (6.1) 7 (9.9) 2 (13.3) .43
Previous stroke 27 (11.5) 16 (10.8) 10 (14.1) 1 (6.7) .65
Cognitive dysfunction 11 (4.7) 3 (2.0) 7 (9.9) 1 (6.7) .04
Angiographic characteristics
3VD 191 (81.6) 133 (89.9) 44 (62.0) 14 (93.3)
<.001
2VD with prox LAD 43 (18.4) 15 (10.1) 27 (38.0) 1 (6.7)
Test results, mean (SD)
LV function ejection
fraction, %
49.2 (11.2) 48.4 (11.1) 51.3
(11.0)
46.8 (12.4) .15
BMI 29.6 (6.8) 30.1 (6.0) 29.8 (8.0) 24.1 (5.4) .005
SYNTAX score 28.6 (10.7) 30.9 (10.4) 23.5 (9.9) 29.2 (9.6) <.001
EuroSCORE 2.2 (2.4) 1.9 (1.9) 2.4 (2.9) 3.9 (4.0) .006
STS score
Mortality 1.6 (1.7) 1.4 (1.5) 1.8 (2.0) 2.8 (1.7) .005
Morbidity and mortality 12.0 (8.4) 11.8 (7.7) 11.6 (9.5) 17.0 (8.9) .11
Abbreviations: 2VD with prox LAD, 2 epicardial
coronary vessels with involvement of the proximal left
anterior descending artery; 3VD, 3 epicardial coronary
vessels; BMI, body mass index (calculated as weight
in kilograms divided by height in meters squared);
CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; EuroSCORE,
European System for Cardiac Operative Risk Evaluation
score; LV, left ventricular; MI, myocardial infarction;
PCI, percutaneous coronary intervention; STEMI,
ST-segment elevation myocardial infarction; STS,
Society of Thoracic Surgeons; SYNTAX, Synergy
Between PCI With Taxus and Cardiac Surgery
clinical trial.
Table 2. Paired Analysis Between Heart Team Treatment Decision vs Original Treatment Decision for Individual Cases
Decision
Between heart team and original treating interventional cardiologist Cohen κ
P valueAgreement 95% CI Disagreement 95% CI Value 95% CI
Heart team treatment vs original treatment, No. (%) 163 (70) 78.2-89.8 71 (30) 11.2-30.7 0.478 0.336-0.540 .006
Cases, No./Total No. (%)
Unanimous 109/163 (66.9) 59.08-74.04 28/71 (39.4) 28.0-51.8 NA NA
<.001
Majority 54/163 (33.1) 26.0-40.9 42/71 (60.6) 48.25-71.97 NA NA
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Agreement and disagreement by original treatment receivedA

















Frequency of agreement and disagreementB
P <.001 for agreementAgreement
Disagreement
Agreement and disagreement were defined as the
concordance or discordance of treatment
recommendations between the heart team and the
original treating interventional cardiologist.
Agreement and disagreement between 2
interventional cardiologists were defined as the
concordance or discordance of treatment
recommendations between the heart team
interventional cardiologist and the original treating
interventional cardiologist. Error bars represent SEs.
CABG indicates coronary artery bypass grafting and
PCI, percutaneous coronary intervention. A,
Agreement and disagreement by original treatment
received. B, Frequency of agreement and
disagreement.
Figure 3. Treatment Recommendations
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cardiologist
Frequency of agreement and disagreement in treatment recommendations between types of expertsC
P = .72 for pairwise comparisons Agreement
Disagreement
Error bars represent SEs. CABG indicates coronary
artery bypass grafting; CS, cardiovascular surgeon; HT,
heart team; IC, interventional cardiologist; and PCI,
percutaneous coronary intervention. A, Overall
frequency of treatment recommendations. B,
Frequency of treatment recommendations by type of
expert within heart team. C, Frequency of agreement
and disagreement in treatment recommendations
between types of experts.
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The frequency with which the different heart team members chose the 3 treatment strategies
is summarized in Figure 3B. Individual heart team members did not significantly differ in the
frequency with which they selected a particular treatment (eg, CABG was selected for 129 of 234
cases [55.1%] reviewed by noninvasive cardiologists, 143 of 234 cases [61.1%] reviewed by
cardiovascular surgeons, and 122 of 234 cases [52.1%] reviewed by interventional cardiologists;
P = .75). Pairwise comparisons of agreement and disagreement in treatment recommendations
between experts from different domains are shown in Figure 3C. The pairwise comparisons were not
significantly different (eg, for the pairing of a heart team interventional cardiologist vs an original
treating interventional cardiologist, treatment agreement was 152 of 234 cases [65.0%] and
treatment disagreement was 82 of 234 cases [35.0%]; for the pairing of a heart team cardiovascular
surgeon vs an original treating interventional cardiologist, treatment agreement was 142 of 234 cases
[60.7%] and treatment disagreement was 92 of 234 cases [39.3%]; P = .72).
Of the 179 screened patients included in the study, patient preference was known in 173 cases
(96.6%); in only 16 of 169 cases (8.9%) did the original treating interventional cardiologist indicate
that patient preference was an important factor in their treatment decisions. The consideration of
patient preference as an important variable in treatment decisions was more frequent in cases in
which the heart team agreed with the original treating interventional cardiologist (10 of 179 cases
[5.6%]) compared with those in which the heart team disagreed with the original treating
interventional cardiologist (6 of 179 cases [3.3%]).
Discussion
To our knowledge, this cross-sectional study conducted at a high-volume tertiary care center is the
first to compare the agreement between treatment decisions made by a heart team with those made
by an original treating interventional cardiologist. The heart team model is recommended for the
treatment of structural heart interventions and multivessel CAD in cardiology guidelines
worldwide.1-3,27,28 Data regarding the heart team approach, although increasing, are still limited.5,29
Furthermore, the extent of difference in the decisions of a heart team compared with those of an
individual physician was previously unknown.
At our center, the treatment recommended by the heart team differed from that of the original
treating interventional cardiologist in 30.3% of cases. This finding has important practical
implications. If heart team recommendations were found to be associated with improvements in
outcomes, there may be a subset of patients for whom the heart team approach would be most
beneficial. Given the extensive resources required for heart team implementation, selection for this
subset of patients may maximize heart team efficiency.
Based on a post hoc analysis, the subset of cases in which the heart team decision differed from
the original treatment decision was associated with an increased frequency of discordant treatment
decisions at the physician or surgeon level. In cases in which the heart team disagreed with the
original treatment decision, unanimous decisions within the heart team were less frequent than in
cases in which they agreed with the original decision. This finding suggests that competing
viewpoints exist in such cases. Furthermore, disagreement between the heart team and the original
treating interventional cardiologist was associated with a more than 4-fold greater disagreement
between the heart team interventional cardiologist and the original treating interventional
cardiologist. In addition, disagreement between the heart team decision and the original treatment
decision was 2-fold greater among patients in whom the original treatment was PCI (45.1%) or
medication therapy (40.0%) compared with CABG (22.3%). In patients for whom PCI and
medication therapy need to be considered, the balancing of competing risks, benefits, and
compromises may be more complex, challenging, or frequent; these dilemmas may also be present
but may occur less frequently when CABG is chosen.
Although heart team decisions adhered to the Appropriate Use Criteria for Coronary
Revascularization in 99.3% of the cases, 29.2% of patients who received recommendations for PCI
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had conditions that were categorized as uncertain according to the criteria, and 5.7% of patients had
conditions that were categorized as inappropriate.13 Because the appropriate use criteria are based
on anatomical factors that define prognostic implications, degree of ischemia, presence of
symptoms, and baseline medication therapies, they do not capture all variables, such as comorbidity,
frailty, life expectancy, surgical risk, patient preference, and social context, which are often important
considerations in the final therapeutic decision.19
One hypothesized outcome of a heart team review may be that the provision of varying
perspectives will help to reconcile context-specific factors during the consideration of multiple
treatment options. In this study, the differences between the heart team decisions and the original
treatment decisions were not associated with an overall difference in the frequency with which PCI
or CABG was recommended. Although the heart team recommended medication therapy with
higher frequency than the original treating interventional cardiologist, the numbers were too small
to be meaningful. The difference was also not associated with expert domain–specific preferences
for particular treatment strategies. Furthermore, paired analyses revealed agreement between
different expert domains in approximately two-thirds of cases in all comparisons. This finding
suggests that variance in the final heart team decision is equally dependent on all heart
team members.
Despite the challenges of addressing uncertain cases, observational studies have indicated that
the heart team model for decision-making is feasible and that decisions are implemented in most
cases (93%). Heart team decisions are also reproducible 74% to 80% of the time.4,12-14 Some
variability may be justified because definable factors, such as coronary complexity (ie, SYNTAX
score), only account for a portion of the clinical decision.30
The conflicting treatment decisions observed in uncertain cases of multivessel CAD have been
recognized by guidelines, position statements, and clinicians.1,2,31 If use of the heart team approach
were found to be associated with improvements in outcomes, selection of these cases a priori would
likely require a scoring tool that uses common clinical characteristics (eg, age, frailty, cognitive
dysfunction, and SYNTAX score) to quantify the therapeutic dilemma. Because multivessel CAD
accounts for approximately 25% to 60% of patients with CAD,18 such a tool would have wide
applicability.
The novel design of the heart team decision-making process underlies the strength of this study.
While heart team meetings at most centers are face to face,14 the initial online structured case
presentation used in this study was essential to answering our study question. First, it resulted in
efficient completion (98.7%) of a high volume of cases. The efficiency of this model is also
highlighted by the fact that face-to-face meetings to reconcile treatment decisions were necessary
in only 13% of the most difficult cases. While the model may still need to evolve, asynchronous
aggregate decisions may potentially complement existing heart team operations by facilitating time-
sensitive decisions at high-volume centers. Second, the online case presentation served to control
for the social factors that can have negative implications for true group decision-making. Social
factors can undermine the diversity of input in group decision-making and the benefits of collective
intelligence.32,33 Furthermore, to answer our study question, the heart team decisions needed to
reflect true group decisions rather than the decisions of a few influential individuals.34,35 This
outcome was accomplished through randomized heart team membership, blinding of heart team
members to ensure independent decision-making, and exposure to the input of other heart team
members only after independent review.
No data are currently available to inform the structure and function of optimal heart team
operations. Hence, our study was guided by the increasing body of empirical data in the cognitive
sciences that have guided optimal group decision-making in other settings.7,8,11,32,36-38 There is a
cognitive advantage to maximizing diversity through pooled decision-making.8,38,39 The ability for
individuals to independently submit their decisions may reduce the momentum bias that the group
can have on the individual.33,40 The opportunity for heart team members to revise their decisions
after independent thought also allows them to consider alternative perspectives. Pooled aggregated
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decisions that are reached after each team member has had the opportunity to consider alternative
viewpoints have been associated with more accurate results compared with pooled independent
decisions alone.36
Limitations
This study has several limitations. First, although the study suggests that the heart team approach is
associated with positive results, it remains unknown whether this approach is more beneficial than
others. Answering this question would require a randomized clinical trial that examined heart team
decisions vs individual decisions. Second, heart team decisions were often made independently of
patient preferences. When our screened cohort was interviewed, it appeared that patient preference
was an important factor in approximately 9% of decisions made by the original treating
interventional cardiologist. Third, our study was performed at a single tertiary care referral center and
will need to be repeated in other settings. Fourth, there was a substantial delay between the time of
the original treatment decision and the time of the heart team review, which may create questions
regarding whether evolving data were associated with changes in decisions. However, by 2012, the
implications of the most important contemporary prognostic indicators with consequences for
treatment decisions (ie, the presence of diabetes, left ventricular dysfunction, and anatomical
complexity, as measured by SYNTAX score) were already known.21,41,42
Conclusions
To our knowledge, this study is the first to suggest that heart team treatment recommendations may
be different than those of the original treating interventional cardiologist in up to 30% of cases. This
subset of cases was associated with more divergent opinions within the heart team and between
interventional cardiologists. Moreover, when the heart team disagreed with the original treating
interventional cardiologist, the original treatment was more frequently PCI or medication therapy
and less frequently CABG, which may suggest that the presence of competing risks and benefits may
underlie considerations of alternate treatment recommendations. Whether heart team reviews are
associated with improvements in clinical outcomes, how heart team recommendations can best be
used, and how patients should be selected for review a priori are questions that need to be further
examined.
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